Increasing the etanercept dose in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomised clinical trial

• Egile Nagusiak: Bastiaan T. van Dijk (Egilea), Sytske Anne Bergstra (Egilea), J. Merlijn van den Berg (Egilea), Dieneke Schonenberg-Meinema (Egilea), Lisette W.A. van Suijlekom-Smit (Egilea), Marion A.J. van Rossum (Egilea), Yvonne Koopman-Keemink (Egilea), Rebecca ten Cate (Egilea), Cornelia F. Allaart (Egilea), Daniëlle M.C. Brinkman (Egilea), Petra C.E. Hissink Muller (Egilea)
• Formatua: Liburua
• Argitaratua: BMC, 2024-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background Etanercept has been studied in doses up to 0.8 mg/kg/week (max 50 mg/week) in juvenile idiopathic arthritis (JIA) patients. In clinical practice higher doses are used off-label, but evidence regarding the relation with outcomes is lacking. We describe the clinical course of JIA-p...